cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas

Valentina Manfè, Edyta Biskup, Ayalah Willumsgaard, Anne Guldhammer Skov, Dario Palmieri, Pierluigi Gasparini, Alessandro Laganá, Anders Woetmann, Niels Ødum, Carlo Maria Croce, Robert Gniadecki

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Successful/effective cancer therapy in low grade lymphoma is often hampered by cell resistance to anti-neoplastic agents. The crucial mechanisms responsible for this phenomenon are poorly understood. Overcoming resistance of tumor cells to anticancer agents, such as proteasome inhibitors, could improve their clinical efficacy. Using cutaneous T-cell lymphoma (CTCL) as a model of the chemotherapy-resistant peripheral lymphoid malignancy, we demonstrated that resistance to proteasome inhibition involved a signaling between the oncogene cMyc and miR-125b-5p. Bortezomib repressed cMyc and simultaneously induced miR-125b-5p that exerted a cytoprotective effect through the downmodulation of MAD4. Overexpression of cMyc repressed miR-125b-5p transcription and sensitized lymphoma cells to bortezomib. The central role of miR-125b-5p was further confirmed in a mouse model of T-cell lymphoma, where xenotransplantation of human CTCL cells overexpressing miR-125b-5p resulted in enhanced tumor growth and a shorter median survival. Our findings describe a novel mechanism through which miR-125b-5p not only regulates tumor growth in vivo, but also increases cellular resistance to proteasome inhibitors via modulation of MAD4.

Original languageEnglish
Article numbere59390
JournalPLoS ONE
Volume8
Issue number3
DOIs
StatePublished - 19 Mar 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas'. Together they form a unique fingerprint.

Cite this